- Home
- HQI vs IPHA Comparison
HQI vs IPHA Comparison
Compare HQI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- IPHA
- Stock Information
- Founded
- HQI 2002
- IPHA 1999
- Country
- HQI United States
- IPHA France
- Employees
- HQI N/A
- IPHA N/A
- Industry
- HQI Professional Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- IPHA Health Care
- Exchange
- HQI Nasdaq
- IPHA Nasdaq
- Market Cap
- HQI 172.8M
- IPHA 191.0M
- IPO Year
- HQI N/A
- IPHA 2019
- Fundamental
- Price
- HQI $14.48
- IPHA $2.28
- Analyst Decision
- HQI Strong Buy
- IPHA Strong Buy
- Analyst Count
- HQI 2
- IPHA 1
- Target Price
- HQI $18.00
- IPHA $11.50
- AVG Volume (30 Days)
- HQI 18.7K
- IPHA 5.5K
- Earning Date
- HQI 11-06-2024
- IPHA 09-12-2024
- Dividend Yield
- HQI 1.76%
- IPHA N/A
- EPS Growth
- HQI N/A
- IPHA N/A
- EPS
- HQI 0.37
- IPHA N/A
- Revenue
- HQI $36,133,000.00
- IPHA $36,202,722.00
- Revenue This Year
- HQI N/A
- IPHA N/A
- Revenue Next Year
- HQI $7.62
- IPHA $105.84
- P/E Ratio
- HQI $37.50
- IPHA N/A
- Revenue Growth
- HQI 3.96
- IPHA 6.88
- 52 Week Low
- HQI $11.39
- IPHA $1.81
- 52 Week High
- HQI $17.45
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- HQI 58.63
- IPHA 50.55
- Support Level
- HQI $13.46
- IPHA $2.22
- Resistance Level
- HQI $14.73
- IPHA $2.41
- Average True Range (ATR)
- HQI 0.60
- IPHA 0.12
- MACD
- HQI 0.02
- IPHA 0.00
- Stochastic Oscillator
- HQI 87.50
- IPHA 52.94
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The primary source of revenue for the company is royalty fees based on the operation of its franchised offices.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.